Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...